78 related articles for article (PubMed ID: 18303603)
41. Against: The case for cytoreductive nephrectomy for the management of metastatic renal cell carcinoma.
Carver BS
J Urol; 2009 Sep; 182(3):833-4. PubMed ID: 19616224
[No Abstract] [Full Text] [Related]
42. The cough from hell: diazepam for intractable cough in a patient with renal cell carcinoma.
Estfan B; Walsh D
J Pain Symptom Manage; 2008 Nov; 36(5):553-8. PubMed ID: 18440768
[TBL] [Abstract][Full Text] [Related]
43. [Renal cell carcinoma and antiangiogenic agents: ongoing controversies are seeking answers for improvement of therapeutic management].
Audenet F; Rouprêt M; Méjean A
Prog Urol; 2009 Oct; 19(9):596-605. PubMed ID: 19800548
[TBL] [Abstract][Full Text] [Related]
44. N-methylformamide-induced hypophosphatemia.
Sternberg CN; Yagoda A
Cancer Treat Rep; 1985 Mar; 69(3):343-4. PubMed ID: 3978663
[No Abstract] [Full Text] [Related]
45. Kidney cancer: decreased incidence of skeletal-related events in mRCC.
Yuasa T; Urakami S
Nat Rev Urol; 2014 Apr; 11(4):193-4. PubMed ID: 24619376
[No Abstract] [Full Text] [Related]
46. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
Oudard S; Medioni J; Aylllon J; Barrascourt E; Elaidi RT; Balcaceres J; Scotte F
Expert Rev Anticancer Ther; 2009 Jun; 9(6):705-17. PubMed ID: 19496707
[TBL] [Abstract][Full Text] [Related]
47. Prognostic factors for survival in metastatic renal cell carcinoma: update 2008.
Bukowski RM
Cancer; 2009 May; 115(10 Suppl):2273-81. PubMed ID: 19402065
[TBL] [Abstract][Full Text] [Related]
48. [The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies].
Ferrière JM; Wallerand H; Bernhard JC; Cornu JN; Rouprêt M; Ravaud A
Prog Urol; 2008 Jul; 18 Suppl 4():S88-91. PubMed ID: 18706377
[TBL] [Abstract][Full Text] [Related]
49. Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.
Drummond M; Evans B; LeLorier J; Karakiewicz P; Martin D; Tugwell P; MacLeod S
Can J Clin Pharmacol; 2009; 16(2):e273-81; discussion e282-4. PubMed ID: 19439771
[TBL] [Abstract][Full Text] [Related]
50. Debulking nephrectomy followed by a "watch and wait" approach in metastatic renal cell carcinoma.
Wong AS; Chong KT; Heng CT; Consigliere DT; Esuvaranathan K; Toh KL; Chuah B; Lim R; Tan J
Urol Oncol; 2009; 27(2):149-54. PubMed ID: 18439851
[TBL] [Abstract][Full Text] [Related]
51. ESMO guidelines on renal cell carcinoma: the paradox of the fine line that separates scientific robustness from cost-efficiency analysis.
Grande E; Escudier B
Ann Oncol; 2021 Dec; 32(12):1466-1467. PubMed ID: 34718116
[No Abstract] [Full Text] [Related]
52. The Authors Respond.
Hansen RN; Hackshaw MD; Sullivan SD; Ramsey SD
J Manag Care Spec Pharm; 2015 Sep; 21(9):844. PubMed ID: 26536677
[No Abstract] [Full Text] [Related]
53. The role of socioeconomic status in renal cell carcinoma.
Hellenthal NJ; Bermejo CE
Urol Oncol; 2012; 30(1):89-94. PubMed ID: 21908209
[TBL] [Abstract][Full Text] [Related]
54. Angiogenesis inhibition in non-clear cell renal cancer.
Stadler W
Clin Adv Hematol Oncol; 2008 Jul; 6(7):507-9. PubMed ID: 18654117
[No Abstract] [Full Text] [Related]
55. ["... and now about the costs!"].
Rohde D
Aktuelle Urol; 2008 Jan; 39(1):2 p preceding table of contents. PubMed ID: 18303603
[No Abstract] [Full Text] [Related]
56. The Costly War Against Cancer Treatment: The Example of Metastatic Renal Cell Carcinoma in Portugal.
Barata PC; Alpuim Costa D; Passos Coelho JL; Da Luz R
Acta Med Port; 2018 Aug; 31(7-8):373-375. PubMed ID: 30189164
[No Abstract] [Full Text] [Related]
57. Advanced renal cell carcinoma in Australia, 2015: what should we do?
Davis ID
Asia Pac J Clin Oncol; 2014 Dec; 10(4):285-8. PubMed ID: 25392943
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
